Connect with us

International

Big Pharma’s ‘Narrative’ Is Failing

Big Pharma’s ‘Narrative’ Is Failing

Published

on

Big Pharma's 'Narrative' Is Failing Tyler Durden Sun, 08/09/2020 - 23:45

Authored by Bretigne Shaffer via LewRockwell.com,

So now we don’t have to listen to what those doctors said in front of the US Supreme Court, because it turns out that one of them has some whacky beliefs about sex with demons causing reproductive disorders. What a relief.

I’m not going to pretend that the things Dr. Stella Immanuel has said don’t sound just a little  crazy to me. They do.

But I’ve been observing this game long enough to have a pretty good idea of how this works:

Someone says something that contradicts the dominant narrative (in this case, the narrative about medical science), and the machine that supports that narrative goes into overdrive to discredit them, with whatever information they can dig up–as long as it doesn’t involve discussing the actual substance of what the person has said.

I understand that for some people, maybe even for a great many, that is the end of the conversation.

So for everyone who is satisfied with the “fringe doctors promoting hydroxychloroquine also believe demon sex causes fybroids” narrative–please, stop here. Your ride is over, and you may go on believing that this group of doctors and other professionals has been thoroughly discredited by these statements.

For everyone else, if you are at all interested in why such a coordinated effort has been launched to silence and discredit this group, why - even before the sex demon stuff was uncovered - videos of the group’s press conference were quickly yanked from YouTube, and why their own website was taken down without warning by its host, SquareSpace, (their new website can now be found here) then please keep reading.

WHAT THE AMERICA’S FRONTLINE DOCTORS GROUP SAID:

What follows is a brief summary of the key points made by the group America’s Frontline Doctors at their press conference last week. I will not comment on the validity of their claims, however founder Dr. Simone Gold has provided support for much of what the group said, in a white paper that can be found here.

1. They believe that hydroxychloroquine is an effective treatment for Covid-19.

This is the claim made by several of the speakers, including Dr. Immanuel, based on their own clinical experience, as well as on multiple published studies. Many of those studies are listed here, and here.

2. State licensing boards are using their power to forcibly prevent people from having access to this drug.

According to Dr. Gold, many states have empowered their pharmacists to not honor prescriptions for hydroxychloroquine to be used in treating Covid-19. This, she says, is unprecedented:

“It has never happened that a state has threatened a doctor for prescribing a universally accepted safe generic cheap drug off-label.”

Meanwhile, says Gold, the drug is available over the counter in many other countries, including Iran and Indonesia, where it can be found “in the vitamin section”.

3. There is a coordinated campaign to discredit and suppress information about the drug hydroxychloroquine as a possible treatment for Covid-19:

“If it seems like there is an orchestrated attack going on against hydroxychloroquine,” said Dr. James Todaro, “it’s because there is.”

Dr. Todaro is speaking from experience. He was the co-author of a March 13 white paper arguing for the use of hydroxychloroquine against Covid-19. The paper was made public on Google Docs, received a lot of attention, and was then removed–without warning–by Google. (It has since been put back up.)

4. The World Health Organization  halted its trials of hydroxychloroquine based on a blatantly fraudulent study that relied on data that it appears never even existed.

Bear in mind that this is the authority upon which YouTube CEO Susan Wojcicki has said she bases her company’s policy on “misinformation”.

The WHO later resumed trials after independent investigators discovered the problems and the study’s authors retracted it.

5. We should be able to have a free and open discussion about this.

Dr. Dr. Joseph Lapado from UCLA, sums it up:

“We’ve been using (hydroxychloroquine) for a long time. But all of a sudden it’s been escalated to this area of looking like some poisonous drug. That just doesn’t make sense… At the very least, we can live in a world where there are differences of opinion about the effectiveness of hydroxychloroquine, but still allow more data to come, still allow physicians who feel they have expertise with it to use that medication, and still, you know, talk and learn and get better at helping people with Covid-19.”

WHY THE ALL-OUT MEDIA ASSAULT ON THE FRONTLINE DOCTORS?:

The influence that the pharmaceutical industry wields over media outlets is no secret. As of 2018, an estimated 70% of all news advertising in the US came from pharmaceutical companies. I have written elsewhere about how “reporting” on medical issues can be difficult to distinguish from outright marketing for drug companies.

Social-media platforms are not immune to this influence, whether it comes via advertising dollars; “partnerships” such as that between the CDC Foundation and MailChimp (which like many other platforms, has an explicit policy of censoring content about vaccines that does not align with the positions of the CDC and the WHO); direct investment, such as that of Google’s parent company Alphabet; or indeed at the behest of politicians such as Congressman Adam Schiff, who last year wrote to the CEOs of Amazon, Facebook and Google, requesting that those companies censor information and products that did not conform to the officially sanctioned position on vaccines. All three complied.

So it should come as small surprise that both Google and YouTube have now taken to removing content supportive of hydroxychloroquine, a drug that is no longer covered by patent, and can be made and sold by any generic producer, for a fraction of the price that Gilead, for example, might charge for its still-patented Remdesivir.

Twitter and Facebook have likewise removed posts about the drug, most notably–and with no visible sense of irony–removing posts of the video in which the Frontline Doctors speak out about widespread media censorship of the topic. (You can now see those videos on Bitchute.)

One need not have an opinion on the merits of the drug hydroxychloroquine in order to recognize that something very odd is happening here. Something that doesn’t seem to have anything to do with free and open inquiry or honest scientific discourse.

Many argue that the politicization of this drug is founded in a desire to unseat President Trump, that the opposition to it is primarily because it was endorsed by Trump, and if it is deemed to be a failure (or even better, dangerous to patients) it will be a powerful strike against the president. That may well be part of what has motivated this. But there is another motivation, having to do with the desire to push a more expensive medication onto the market, and to push a new vaccine on the world’s population.

More broadly, it has to do with the narrative that those in the business of selling drugs demand we believe: that we are all in desperate need of their products (but only the ones still under patent) if we are to be healthy–or indeed, if we are to survive at all.

If it turns out that this “new” virus is easily treatable, with hydroxychloroquine or anything else, then the industry’s dreams go up in smoke. If hydroxychloroquine turns out to be a safe and effective way of treating Covid-19 (as multiple studies and the experience in many other countries outside of the US indicate it may be) then there is much less reason for anyone to receive a vaccine for it, let alone the entire world’s population. Likewise, there is no pressing need to develop a new, more expensive treatment.

But even more than that: If it turns out that hydroxychloroquine is after all a safe and effective treatment for Covid-19, then this whole episode - the silencing of dissenting voices, the “fact-checking” on social media, the campaigns against “misinformation” - will be revealed in plain sight, for what it has always been: Nothing more than a well-funded marketing campaign and damage-control effort on behalf of the industry that wants you to believe that you need to use its expensive products in order to go on living.

So when a group of doctors took to the steps of the US Supreme Court and told the world how they were having success using a cheap anti-malarial that had been in use for 65 years to treat the most deadly contagion of our generation, it was a massive blow to the narrative upon which the pharmaceutical purveyors’ success depends. And over the next few days, as viewers engaged in a race with the censors, quickly downloading videos before they were removed, to post them on other platforms… it became clear that the censors and the gatekeepers had lost control of the conversation.

This is not only about hydroxychloroquine. Every time media outlets or social-media platforms engage in outright censorship of content, in a way that happens to benefit pharmaceutical companies, both parties lose just a little more credibility. The actions we are witnessing now are not the actions of an industry confident in the value of what it provides to the world. They are the actions of a desperate, threatened creature. They are the actions of an entity that is not strengthened by the truth, but weakened by it. That is what these (increasingly obvious) acts of censorship tell us. What we are witnessing are the pangs of a lumbering, wounded, behemoth.

Read More

Continue Reading

International

Analyst reviews Apple stock price target amid challenges

Here’s what could happen to Apple shares next.

Published

on

They said it was bound to happen.

It was Jan. 11, 2024 when software giant Microsoft  (MSFT)  briefly passed Apple  (AAPL)  as the most valuable company in the world.

Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion. 

It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion. 

"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.

The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.

Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue. 

Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.

Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.

“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.

A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.

Future Publishing/Getty Images

Big plans for China

Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.

Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.

Related: Tech News Now: OpenAI says Musk contract 'never existed', Xiaomi's EV, and more

The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.

Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.

Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.

"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads. 

"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.

Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify  (SPOT)  and other music streaming rivals via restrictions on the App Store.

The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.

Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com

The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.

BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market. 

Analyst says Apple selloff 'overdone'

Concurrently, prices for previous models are typically reduced by about $100 with each new release. 

This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.

More Tech Stocks:

Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.

This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China. 

BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.

The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.

On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”

The firm said that investors' growing preference for AI-focused stocks like Nvidia  (NVDA)  has led to a reallocation of funds away from Apple. 

In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.

And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.

“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…

Published

on

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

Credit: IVI

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

 

The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.

 

There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.

 

“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”

 

In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.

 

There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.

 

Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.

 

Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”

 

As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

CONTACT

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int


Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Trending